Welcome to our dedicated page for APOLLOMICS news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. (APLMW, associated with Apollomics’ Nasdaq-listed shares under APLM) generates news that reflects its role as a clinical-stage biopharmaceutical company focused on oncology drug development. Company announcements frequently describe progress and challenges across its pipeline of oncology candidates, including vebreltinib (APL-101), an oral, highly selective c-Met inhibitor in a global Phase 2 multicohort trial for non-small cell lung cancer and other tumors with MET alterations.
Investors following Apollomics-related news can expect updates on clinical data, program prioritization and strategic decisions. The company has reported interim results from cohorts in its SPARTA trial, including activity in non-central nervous system MET fusion tumors and MET-amplified non-small cell lung cancer, as well as analyses in patients with MET exon 14 skipping mutations. News releases also cover outcomes from other programs, such as the Phase 3 bridging trial of uproleselan in China in relapsed or refractory acute myeloid leukemia, where the trial did not demonstrate favorable benefit and the program is being wrapped up.
Beyond clinical results, Apollomics’ news flow includes collaboration and licensing developments, such as its agreement with LaunXP for development and commercialization of vebreltinib in combination with an EGFR inhibitor in parts of Asia, and subsequent disclosures about payment disputes under that agreement. Financial updates, including annual and interim results, highlight research and development and administrative expenses, net losses and liquidity considerations.
Corporate governance and capital markets actions are also recurring themes. Recent items include reverse share split implementation, Nasdaq listing compliance updates, private placement (PIPE) financings, and changes in the board of directors and executive leadership. Some news has addressed operational continuity, describing earlier plans to seek shareholder approval to wind up the company and later communications indicating a reversal of those plans and continued development of vebreltinib. For readers tracking APLMW and APLM, this news stream provides context on Apollomics’ clinical, financial and corporate trajectory.
Apollomics Inc. (Nasdaq: APLM) presented data on vebreltinib for non-small cell lung cancer (NSCLC) with METex14 skipping mutations at the ESMO Congress 2024. Key findings include:
1. Efficacy in both treatment-naïve and previously treated patients:
- Treatment-naïve: 66.7% overall response rate (ORR), 17.3 months median duration of response (DOR), 13.8 months median progression-free survival (PFS)
- Previously treated: 61.1% ORR, 16.7 months median DOR, 7.4 months median PFS
2. Efficacy regardless of MET gene copy number (GCN):
- GCN<4: 67.8% ORR
- GCN<6: 69.2% ORR
- GCN>4: 100% ORR (5/5 patients)
3. Safety profile: 48.1% of patients experienced grade 3 or higher treatment-related adverse events, with edema being most common (16.7%). No deaths were reported due to treatment-emergent adverse events.
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, both virtually and in-person at the Lotte New York Palace Hotel in New York, NY.
Key details of Apollomics' participation include:
- An on-demand company presentation available from September 9, 2024, at 7:00 am ET
- Presenters: Guo-Liang Yu, PhD (Chairman and CEO) and Matthew Plunkett, PhD (CFO)
- Management will be available for virtual one-on-one meetings
- The presentation will be accessible on the company's website
Apollomics focuses on developing oncology drug candidates for difficult-to-treat and treatment-resistant cancers.
Apollomics Inc. (Nasdaq: APLM) reported its first half 2024 financial results and clinical progress for vebreltinib. Key highlights include:
1. Promising preliminary results from the vebreltinib program for tumors with Met dysregulation, including non-CNS MET fusion tumors and NSCLC with MET amplification.
2. Cash position of $25.9 million as of June 30, 2024, with runway into Q3 2025.
3. R&D expenses of $16.9 million and G&A expenses of $10.2 million for H1 2024.
4. Net loss of $(35.2) million, or $(0.38) per share, including a $10 million impairment loss for uproleselan.
5. Strategic focus on vebreltinib for NSCLC patients with Met Amplification.
6. Raised $5.8 million in a PIPE financing in May 2024.
Apollomics Inc. (Nasdaq: APLM) announced positive preliminary data from its Phase 2 SPARTA trial of vebreltinib in patients with non-CNS MET fusion solid tumors. The study showed a 43% overall response rate, with six confirmed responses out of 14 patients. Key highlights include:
- One complete response in metastatic non-small cell lung cancer (NSCLC)
- Five partial responses across NSCLC, pancreatic cancer, and intrahepatic bile duct cancer
- Median overall survival of 12.4 months
- Median progression-free survival of 4.5 months
- Median duration of response of 5.6 months
- Longest ongoing response of 18 months
The company believes these results support vebreltinib's potential as a targeted therapy for tumors with MET alterations, which occur in 0.1-0.3% of solid tumors.
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company focusing on oncology drug candidates for difficult-to-treat and treatment-resistant cancers, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-15, 2024, in Boston, MA.
Key details of Apollomics' presentation:
- Date and Time: Tuesday, August 14, 2024, at 9:30 am ET
- Location: InterContinental Boston Hotel
- Presenter: Matthew Plunkett, PhD, Chief Financial Officer
The company management will be available for one-on-one meetings during the conference. Interested investors can contact their Canaccord Genuity representative to schedule meetings. A webcast link for the presentation will be available on the company's website under the Investors section on the Events page.
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement. The company now has until January 13, 2025 to meet the $1.00 per share minimum bid price for its Ordinary Shares. This extension follows a previous notice of non-compliance received on January 16, 2024.
To regain compliance, Apollomics must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before the deadline. If unsuccessful, the company may face delisting, with an option to appeal to a Nasdaq Hearings Panel. Apollomics is actively monitoring its stock price and exploring options to meet the requirement, though success is not guaranteed.
Apollomics (Nasdaq: APLM) announced a revised strategic focus on the clinical development of vebreltinib for NSCLC patients with Met Amplification mutations and significant changes in its executive leadership. The SPARTA Phase 2 trial will concentrate on this high-need patient population. Co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., will transition to consulting roles in August. These changes are part of a broader cost-reduction strategy expected to cut operating expenses by over 50% and extend funding until Q3 2025.
Apollomics aims to generate additional clinical data to support regulatory submissions, with updates anticipated in 2024 and 2025. The departures of key executives are aligned with the company's resource needs and focus on maximizing the efficient use of capital.
Apollomics presented promising data on vebreltinib at the 2024 ASCO Annual Meeting. The Phase 2 and 2/3 trials showed strong efficacy and safety in treating MET-altered tumors, particularly in non-small cell lung cancer (NSCLC) and glioblastoma patients. Key results included a 75% overall response rate (ORR) for NSCLC with MET exon 14-skipping mutations, and a 6.31 months median overall survival (OS) in glioblastoma patients with PTPRZ1-MET Fusion gene. No new safety concerns were identified. Apollomics aims to continue advancing vebreltinib's clinical development.
Apollomics, a clinical-stage biopharmaceutical company focusing on oncology drug candidates, will present at the 2024 BIO International Convention. The event will take place from June 3-6, 2024, in San Diego, California.
Apollomics' presentation, led by President Sanjeev Redkar, PhD, is scheduled for June 4 at 3:15 p.m. in Theater 2, Hall A, at the San Diego Convention Center.
Management will also be available for one-on-one meetings with registered attendees, which can be scheduled through the BIO One-on-One Partnering™ system or by contacting the provided email.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
FAQ
What is the current stock price of APOLLOMICS (APLMW)?
What is the market cap of APOLLOMICS (APLMW)?
